New 52 Week Low Today

Longboard Pharmaceuticals Inc LBPH:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EDT
10.59quote price arrow up+0.34 (+3.32%)
Volume
2,899
52 week range
9.96 - 18.95

...

Loading . . .
  • Open10.25
  • Day High10.94
  • Day Low9.96
  • Prev Close10.25
  • 52 Week High18.95
  • 52 Week High Date04/06/21
  • 52 Week Low9.96
  • 52 Week Low Date04/22/21

Key Stats

  • Market Cap179.18M
  • Shares Out16.92M
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-

KEY STATS

  • Open10.25
  • Day High10.94
  • Day Low9.96
  • Prev Close10.25
  • 52 Week High18.95
  • 52 Week High Date04/06/21
  • 52 Week Low9.96
  • 52 Week Low Date04/22/21
  • Market Cap179.18M
  • Shares Out16.92M
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.85
  • P/E (TTM)-12.44
  • Fwd P/E (NTM)-4.15
  • EBITDA (MRQ)-14.40M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest From Longboard Pharmaceuticals Inc

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for neurological diseases. Its pipelines includes LP352, LP143 and LP659. LP352 is an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype (5-HT2c) superagonist for the treatment of developmental and epileptic encephalopathies (DEEs), including Dravet syndrome and Lennox-Gastaut syndrome, among others. LP143 is a centrally acting, full...
Kevin Lind
President
Chad Orevillo
Vice President
Address
6154 Nancy Ridge Drive
San Diego, CA
92121
United States